VeriStrat® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: Pooled analysis of SAKK19/05 and NTR528

Oliver Gautschi; Anne Marie Dingemans; Susanne Crowe; Solange Peters; Heinrich Roder; Julia Grigorieva; Joanna Roder; Francesco Zappa; Miklos Pless; Martin Brutsche; Florent Baty; Lukas Bubendorf; Shu Fang Hsu Schmitz; Kyung Jae Na; David Carbone; Rolf Stahel; Egbert Smit

doi:10.1016/j.lungcan.2012.10.006

VeriStrat^® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: Pooled analysis of SAKK19/05 and NTR528

Oliver Gautschi^*
, Anne Marie Dingemans
, Susanne Crowe
, Solange Peters
, Heinrich Roder
, Julia Grigorieva
, Joanna Roder
, Francesco Zappa
, Miklos Pless
, Martin Brutsche
, Florent Baty
, Lukas Bubendorf
, Shu Fang Hsu Schmitz
, Kyung Jae Na
, David Carbone
, Rolf Stahel
, Egbert Smit

^*Corresponding author for this work

Kantonsspital Luzern
Swiss Group for Clinical Cancer Research
University Hospital Lausanne
Biodesix Inc.
Institute of Oncology of Southern Switzerland
Cantonal Hospital Winterthur
Cantonal Hospital St. Gallen
Universitätsspital Basel
Vanderbilt-Ingram Cancer Center
University Hospital Zürich
VU University Medical Center
Maastricht University

Research output: Contribution to journal › Article › Academic › peer-review

26 Citations (Scopus)

Abstract

Background:

VeriStrat^® is a serum proteomic test used to determine whether patients with advanced non-small cell lung cancer (NSCLC) who have already received chemotherapy are likely to have good or poor outcomes from treatment with gefitinib or erlotinib. The main objective of our retrospective study was to evaluate the role of VS as a marker of overall survival (OS) in patients treated with erlotinib and bevacizumab in the first line.

Patients and methods:

Patients were pooled from two phase II trials (SAKK19/05 and NTR528). For survival analyses, a log-rank test was used to determine if there was a statistically significant difference between groups. The hazard ratio (HR) of any separation was assessed using Cox proportional hazards models.

Results:

117 patients were analyzed. VeriStrat classified patients into two groups which had a statistically significant difference in duration of OS (p=0.0027, HR. =0.480, 95% confidence interval: 0.294-0.784).

Conclusion:

VeriStrat has a prognostic role in patients with advanced, nonsquamous NSCLC treated with erlotinib and bevacizumab in the first line. Further work is needed to study the predictive role of VeriStrat for erlotinib and bevacizumab in chemotherapy-untreated patients.

Original language	English
Pages (from-to)	59-64
Number of pages	6
Journal	Lung Cancer
Volume	79
Issue number	1
DOIs	https://doi.org/10.1016/j.lungcan.2012.10.006
Publication status	Published - Jan 2013
Externally published	Yes

Bibliographical note

Funding Information:
This work was supported by Biodesix Inc. who performed all VS analysis for free. The SAKK19/05 trial was supported by the Swiss State Secretariat for Education and Research (SER) and Roche Pharma (Schweiz) AG .

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1016/j.lungcan.2012.10.006

Cite this

Gautschi, O., Dingemans, A. M., Crowe, S., Peters, S., Roder, H., Grigorieva, J., Roder, J., Zappa, F., Pless, M., Brutsche, M., Baty, F., Bubendorf, L., Hsu Schmitz, S. F., Na, K. J., Carbone, D., Stahel, R., & Smit, E. (2013). VeriStrat^® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: Pooled analysis of SAKK19/05 and NTR528. Lung Cancer, 79(1), 59-64. https://doi.org/10.1016/j.lungcan.2012.10.006

@article{2bdcfdc4a39e469ba89847d2ebb9c604,

title = "VeriStrat{\textregistered} has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: Pooled analysis of SAKK19/05 and NTR528",

abstract = "Background: VeriStrat{\textregistered} is a serum proteomic test used to determine whether patients with advanced non-small cell lung cancer (NSCLC) who have already received chemotherapy are likely to have good or poor outcomes from treatment with gefitinib or erlotinib. The main objective of our retrospective study was to evaluate the role of VS as a marker of overall survival (OS) in patients treated with erlotinib and bevacizumab in the first line. Patients and methods: Patients were pooled from two phase II trials (SAKK19/05 and NTR528). For survival analyses, a log-rank test was used to determine if there was a statistically significant difference between groups. The hazard ratio (HR) of any separation was assessed using Cox proportional hazards models. Results: 117 patients were analyzed. VeriStrat classified patients into two groups which had a statistically significant difference in duration of OS (p=0.0027, HR. =0.480, 95\% confidence interval: 0.294-0.784).Conclusion: VeriStrat has a prognostic role in patients with advanced, nonsquamous NSCLC treated with erlotinib and bevacizumab in the first line. Further work is needed to study the predictive role of VeriStrat for erlotinib and bevacizumab in chemotherapy-untreated patients.",

author = "Oliver Gautschi and Dingemans, \{Anne Marie\} and Susanne Crowe and Solange Peters and Heinrich Roder and Julia Grigorieva and Joanna Roder and Francesco Zappa and Miklos Pless and Martin Brutsche and Florent Baty and Lukas Bubendorf and \{Hsu Schmitz\}, \{Shu Fang\} and Na, \{Kyung Jae\} and David Carbone and Rolf Stahel and Egbert Smit",

note = "Funding Information: This work was supported by Biodesix Inc. who performed all VS analysis for free. The SAKK19/05 trial was supported by the Swiss State Secretariat for Education and Research (SER) and Roche Pharma (Schweiz) AG . ",

year = "2013",

month = jan,

doi = "10.1016/j.lungcan.2012.10.006",

language = "English",

volume = "79",

pages = "59--64",

journal = "Lung Cancer",

issn = "0169-5002",

publisher = "Elsevier Ireland Ltd",

number = "1",

}

Gautschi, O, Dingemans, AM, Crowe, S, Peters, S, Roder, H, Grigorieva, J, Roder, J, Zappa, F, Pless, M, Brutsche, M, Baty, F, Bubendorf, L, Hsu Schmitz, SF, Na, KJ, Carbone, D, Stahel, R & Smit, E 2013, 'VeriStrat^® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: Pooled analysis of SAKK19/05 and NTR528', Lung Cancer, vol. 79, no. 1, pp. 59-64. https://doi.org/10.1016/j.lungcan.2012.10.006

VeriStrat^® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: Pooled analysis of SAKK19/05 and NTR528. / Gautschi, Oliver; Dingemans, Anne Marie; Crowe, Susanne et al.
In: Lung Cancer, Vol. 79, No. 1, 01.2013, p. 59-64.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - VeriStrat® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line

T2 - Pooled analysis of SAKK19/05 and NTR528

AU - Gautschi, Oliver

AU - Dingemans, Anne Marie

AU - Crowe, Susanne

AU - Peters, Solange

AU - Roder, Heinrich

AU - Grigorieva, Julia

AU - Roder, Joanna

AU - Zappa, Francesco

AU - Pless, Miklos

AU - Brutsche, Martin

AU - Baty, Florent

AU - Bubendorf, Lukas

AU - Hsu Schmitz, Shu Fang

AU - Na, Kyung Jae

AU - Carbone, David

AU - Stahel, Rolf

AU - Smit, Egbert

N1 - Funding Information: This work was supported by Biodesix Inc. who performed all VS analysis for free. The SAKK19/05 trial was supported by the Swiss State Secretariat for Education and Research (SER) and Roche Pharma (Schweiz) AG .

PY - 2013/1

Y1 - 2013/1

N2 - Background: VeriStrat® is a serum proteomic test used to determine whether patients with advanced non-small cell lung cancer (NSCLC) who have already received chemotherapy are likely to have good or poor outcomes from treatment with gefitinib or erlotinib. The main objective of our retrospective study was to evaluate the role of VS as a marker of overall survival (OS) in patients treated with erlotinib and bevacizumab in the first line. Patients and methods: Patients were pooled from two phase II trials (SAKK19/05 and NTR528). For survival analyses, a log-rank test was used to determine if there was a statistically significant difference between groups. The hazard ratio (HR) of any separation was assessed using Cox proportional hazards models. Results: 117 patients were analyzed. VeriStrat classified patients into two groups which had a statistically significant difference in duration of OS (p=0.0027, HR. =0.480, 95% confidence interval: 0.294-0.784).Conclusion: VeriStrat has a prognostic role in patients with advanced, nonsquamous NSCLC treated with erlotinib and bevacizumab in the first line. Further work is needed to study the predictive role of VeriStrat for erlotinib and bevacizumab in chemotherapy-untreated patients.

AB - Background: VeriStrat® is a serum proteomic test used to determine whether patients with advanced non-small cell lung cancer (NSCLC) who have already received chemotherapy are likely to have good or poor outcomes from treatment with gefitinib or erlotinib. The main objective of our retrospective study was to evaluate the role of VS as a marker of overall survival (OS) in patients treated with erlotinib and bevacizumab in the first line. Patients and methods: Patients were pooled from two phase II trials (SAKK19/05 and NTR528). For survival analyses, a log-rank test was used to determine if there was a statistically significant difference between groups. The hazard ratio (HR) of any separation was assessed using Cox proportional hazards models. Results: 117 patients were analyzed. VeriStrat classified patients into two groups which had a statistically significant difference in duration of OS (p=0.0027, HR. =0.480, 95% confidence interval: 0.294-0.784).Conclusion: VeriStrat has a prognostic role in patients with advanced, nonsquamous NSCLC treated with erlotinib and bevacizumab in the first line. Further work is needed to study the predictive role of VeriStrat for erlotinib and bevacizumab in chemotherapy-untreated patients.

UR - https://www.scopus.com/pages/publications/84871061548

U2 - 10.1016/j.lungcan.2012.10.006

DO - 10.1016/j.lungcan.2012.10.006

M3 - Article

C2 - 23122759

AN - SCOPUS:84871061548

SN - 0169-5002

VL - 79

SP - 59

EP - 64

JO - Lung Cancer

JF - Lung Cancer

IS - 1

ER -